Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03239106 · ClinicalTrials.gov registry record · Phase 2
A Study Examining the Medication Apremilast as Treatment for Chronic Itch
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03239106 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT03239106, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Chronic Itch is a debilitating condition affecting many people. Currently, there are no FDA-approved treatments. Apremilast is an FDA-approved oral medication used to successfully treat the inflammatory skin disorder psoriasis and the inflammatory disorder psoriatic arthritis. This study examines if apremiliast taken twice daily relieves chronic itch.
Interventions
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03239106
The ClinicalTrials.gov registry entry for NCT03239106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apremilast is the first listed.
NCT03239106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03239106 about?
NCT03239106 is a clinical study titled "A Study Examining the Medication Apremilast as Treatment for Chronic Itch". Chronic Itch is a debilitating condition affecting many people. Currently, there are no FDA-approved treatments. Apremilast is an FDA-approved oral medication used to successfully treat the inflammatory skin disorder psoriasis and the inflammatory disorder psoriatic arthritis. This study examines if...
What is the current status of trial NCT03239106?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-12-01. Estimated completion is 2019-09-19.
What interventions are being tested in trial NCT03239106?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT03239106?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.